16 unchanged lines
Adverse reactions in ≥ 10% of patients in the GAZYVA containing arm were infusion-related reactions, neutropenia, thrombocytopenia, and diarrhea. The most common Grade 3 to 4 adverse reactions (incidence ≥ 10%) in the GAZYVA containing arm were neutropenia, infusion-related reactions, and thrombocytopenia.
Table 78 Adverse Reactions (Incidence ≥ 5% and ≥ 2% Greater in the GAZYVA Arm) in Patients with CLL (Stage 2)
Body System Adverse Reactions | GAZYVA + Chlorambucil n = 336 | Rituximab product + Chlorambucil n = 321
13 unchanged lines
Urinary Tract Infection | 5 | 1 | 2 | < 1
Table 89 Post-Baseline Laboratory Abnormalities (Incidence ≥ 10% and ≥ 2% Greater in the GAZYVA Arm) in Patients with CLL (Stage 2)
Laboratory Abnormalities | GAZYVA + Chlorambucil n = 336 | Rituximab product + Chlorambucil n = 321
19 unchanged lines
Dose modification due to adverse reactions occurred in 50% of the GAZYVA arm and 42% of the control arm, and discontinuation of any study drug due to adverse reactions occurred in 20% and 17%, respectively.
Table 910 presents selected adverse reactions in GADOLIN. The most common adverse reactions (incidence ≥ 20%) in GAZYVA recipients included infusion-related reactions, fatigue, neutropenia, cough, upper respiratory tract infections, and musculoskeletal pain.
Table 910 Adverse Reactions (Incidence ≥ 10% and ≥ 2% Greater in the GAZYVA Arm) in Patients with Relapsed or Refractory NHL (GADOLIN)
Body System Adverse Reactions , | GAZYVA + Bendamustine followed by GAZYVA monotherapy n = 204 | Bendamustine n = 203
34 unchanged lines
During GAZYVA monotherapy (158 patients), adverse reactions in ≥ 10% of patients included upper and lower respiratory tract infections, cough, neutropenia, musculoskeletal pain, fatigue, diarrhea, rash, and urinary tract infection.
Table 1011 presents selected new or worsening laboratory abnormalities in the GADOLIN trial.
Table 1011 New or Worsening Laboratory Abnormalities (Incidence ≥ 10% and ≥ 2% Greater in the GAZYVA Arm ) in Patients with Relapsed or Refractory NHL (GADOLIN)
Laboratory Abnormalities | GAZYVA + Bendamustine followed by GAZYVA monotherapy n = 204 | Bendamustine n = 203
17 unchanged lines
During combination therapy, 93% of patients received all treatment cycles in the GAZYVA arm, and 92% received all treatment cycles in the rituximab product arm. Of the responding patients who began monotherapy with GAZYVA or rituximab product, 76% and 73%, respectively, completed the full course. Dose modification due to adverse reactions occurred in 74% of the GAZYVA arm and 63% of the rituximab product arm throughout study treatment, and discontinuation of any study drug due to adverse reactions occurred in 18% and 15%, respectively.
Throughout treatment and follow-up, the most common adverse reactions (incidence ≥ 20%) observed at least 2% more in the GAZYVA arm included infusion-related reactions, neutropenia, upper respiratory tract infections, constipation and diarrhea (Table 1112). Neutropenia, infusion-related reactions, febrile neutropenia and thrombocytopenia were the most common Grade 3 to 5 adverse reactions (incidence ≥ 5%) observed more frequently in the GAZYVA arm.
Table 1112 Adverse Reactions (Incidence ≥ 10% and ≥ 2% Greater in the GAZYVA Arm) in Patients with Previously Untreated NHL (GALLIUM)
Body System Adverse Reactions , | GAZYVA + chemotherapy followed by GAZYVA monotherapy n = 691 | Rituximab product + chemotherapy followed by rituximab product monotherapy n = 694
36 unchanged lines
During the monotherapy period, the common adverse reactions (incidence ≥ 10%) observed at least 2% more with GAZYVA were upper respiratory tract infection (40%), cough (23%), musculoskeletal pain (20%), neutropenia (19%), and herpesvirus infection (13%).
Table 1213 summarizes treatment-emergent laboratory abnormalities during treatment and follow-up. The Grade 3 to 4 abnormalities reported at least 2% more in the GAZYVA arm were lymphopenia, leukopenia, neutropenia, thrombocytopenia, and hyperuricemia. Patients in the GAZYVA arm, as compared to the rituximab product arm, had higher incidences of Grade 4 neutropenia (38% vs. 30%, respectively), Grade 4 lymphopenia (33% vs. 22%), and Grade 4 leukopenia (17% vs. 12%).
Table 1213 New or Worsening Laboratory Abnormalities (Incidence ≥ 10% and ≥ 2% Greater in the GAZYVA Arm) in Patients with Previously Untreated NHL (GALLIUM)
Laboratory Abnormalities | GAZYVA+ chemotherapy followed by GAZYVA monotherapy n = 691 | Rituximab product + chemotherapy followed by rituximab product monotherapy n = 694
26 unchanged lines
The most common serious adverse reactions in the GAZYVA arm were: COVID-19 (11 patients [5.5%]), pneumonia (9 patients [4.5%]), neutropenia (7 patients [3.5%]), urinary tract infections (5 patients [2.5%]) and infusion-related reactions (1 patient [0.5%]). No serious adverse reactions were reported for bronchitis, herpes simplex and upper respiratory tract infections. Two fatal adverse reactions of COVID-19 were reported in the GAZYVA arm.
Adverse reaction rates are presented in Table 1314.
Table 1314 Adverse Reactions in Adults with Active Lupus Nephritis Treated with GAZYVA Versus Placebo (≥ 2% Greater in the GAZYVA Arm) in REGENCY and NOBILITY Studies
Body System Adverse Reactions | GAZYVA + standard therapy n = 200 | Placebo + standard therapy n = 193
11 unchanged lines
Neutropenia | 14 | 7 | 6 | 0.5
Childhood-Onset Idiopathic Nephrotic Syndrome
The data described in Table 15 reflect exposure to GAZYVA administered intravenously in patients with childhood-onset INS in the INSHORE study (NCT05627557). In INSHORE, 44 patients received GAZYVA, of which 41 patients were 4 to 18 years of age [see Clinical Studies (14.4)]. Adverse event severity was graded as Grades 1 to 5 defined as mild (1), moderate (2), severe (3), life-threatening (4), and fatal (5).
The most common adverse reactions (incidence ≥ 10% in the GAZYVA arm) are shown in Table 15. There were no Grade 5 adverse reactions in INSHORE.
Table 15 Adverse Reactions in Patients with Childhood-Onset Idiopathic Nephrotic Syndrome Treated with GAZYVA Versus Mycophenolate Mofetil (≥ 10% in the GAZYVA Arm) in the INSHORE study
Body System Adverse Drug Reactions | GAZYVA n = 44 | MMF n = 41
All Grades (%) | Grades 3-4 (%) | All Grades (%) | Grades 3-4 (%)
NA: Not Applicable
Infections and Infestations
Upper Respiratory Tract Infection | 59 | 2 | 63 | 2
Ear Infection | 32 | 2 | 15 | 0
Pneumonia | 25 | 9 | 5 | 0
Influenza | 20 | 0 | 10 | 0
Bronchitis | 14 | 2 | 5 | 0
COVID-19 | 14 | 0 | 12 | 0
Conjunctivitis | 14 | 0 | 7 | 0
Urinary Tract Infection | 11 | 0 | 0 | 0
Injury, Poisoning and Procedural Complications
Infusion Related Reaction | 36 | 0 | NA | NA
Blood and Lymphatic System Disorders
Neutropenia | 18 | 16 | 2 | 2
Specific Adverse Reactions
17 unchanged lines
In the REGENCY study, most common IRR signs or symptoms included headache, nausea and vomiting. In the NOBILITY study, the most common IRR symptoms were pyrexia and tachycardia.
Childhood-Onset Idiopathic Nephrotic Syndrome
In the INSHORE study, all IRRs were Grade 1-2 (mild or moderate) and predominately occurred during/after the first infusion [see Table 15 and Warnings and Precautions (5.3)]. IRRs requiring GAZYVA infusion interruption, rate reduction, or stoppage occurred in 23% of patients. The most common IRR signs or symptoms included pyrexia, vomiting and nausea.
Neutropenia
Chronic Lymphocytic Leukemia
The incidence of neutropenia reported as an adverse reaction in CLL11 was 38% in the GAZYVA treated arm and 32% in the rituximab product treated arm, with the incidence of serious adverse reactions being 1% and < 1%, respectively (Table 79). Cases of late-onset neutropenia (occurring 28 days after completion of treatment or later) were 16% in the GAZYVA treated arm and 12% in the rituximab product treated arm.
Non-Hodgkin Lymphoma
2 unchanged lines
Lupus Nephritis
In the pooled REGENCY and NOBILITY studies, neutropenia and related adverse reactions (i.e., leukopenia, lymphopenia, lymphocyte count decreased, febrile neutropenia, and neutrophil count decreased) were reported in 14% of patients in the GAZYVA arm versus 6% of patients in the placebo arm. Grade 3-4 neutropenia was reported in 7% of patients treated with GAZYVA versus 0.5% of patients in the placebo arm. Neutropenia and related adverse reactions resolved/improved spontaneously or with use of granulocyte colony-stimulating factorsfactor in 96% of patients [see Warnings and Precautions (5.7)].
Childhood-Onset Idiopathic Nephrotic Syndrome
In the INSHORE study, the majority of neutropenia and related adverse reactions (i.e., neutrophil count decreased and agranulocytosis) in both arms were Grade 3 or 4 (severe or life-threatening or due to neutrophil count < 1000 cells/µL; see Table 15). The majority of neutropenia and related events resolved/improved spontaneously and one event resolved with the use of granulocyte colony-stimulating factor [see Warnings and Precautions (5.7)].
Infection
7 unchanged lines
In the pooled REGENCY and NOBILITY studies, infections were reported in 72% of patients in the GAZYVA arm versus 62% of patients in the placebo arm. The most frequently reported infections were upper and lower respiratory tract infections. Grade 3-5 infections were reported in 11% of patients in the GAZYVA arm versus 10% of patients in the placebo arm. Fatal infection events were reported in 1% of patients in the GAZYVA arm versus 0.5% of patients in the placebo arm [see Warnings and Precautions (5.6)].
Childhood-Onset Idiopathic Nephrotic Syndrome
In the INSHORE study, infections were reported in 89% of patients in the GAZYVA arm compared to 76% in the MMF arm. The most frequently reported infections are shown in Table 15 [see Warnings and Precautions (5.6)].
Thrombocytopenia
Chronic Lymphocytic Leukemia
The overall incidence of thrombocytopenia reported as an adverse reaction was higher in the GAZYVA treated arm (14%) compared to the rituximab product treated arm (7%), with the incidence of Grade 3 to 4 events being 10% and 3%, respectively (Table 78). The difference in incidences between the treatment arms is driven by events occurring during the first cycle. The incidence of thrombocytopenia (all grades) in the first cycle was 11% in the GAZYVA and 3% in the rituximab product treated arms, with Grade 3 to 4 rates being 8% and 2%, respectively. Four percent of patients in the GAZYVA treated arm experienced acute thrombocytopenia (occurring within 24 hours after the GAZYVA infusion).
The overall incidence of hemorrhagic events and the number of fatal hemorrhagic events were similar between the treatment arms, with 3 in the rituximab product and 4 in the GAZYVA treated arms. However, all fatal hemorrhagic events in patients treated with GAZYVA occurred in Cycle 1.
22 unchanged lines